Webinar | February 22, 2024

How To Mitigate Risk During ADC Development With Multi-Parameter Stability Characterization

Antibodies And Proteins GettyImages-1364886992

How to mitigate risk during ADC development with multi-parameter stability characterization

There are unique concerns about the developability properties of antibody-drug conjugates (ADCs) due to the conjugation process. With multi-parameter assessment of CQAs, it is possible to examine multiple aspects of ADC stability in parallel, to ensure the final product has the greatest chance at clinical success, while saving time and sample early in development.

This webinar provides a deep dive into the practical considerations of ADC development and characterization.

You’ll learn:

  • What formulation considerations are critical during ADC development
  • How to use high-resolution stability data to compare your ADCs to unconjugated antibodies
  • Which characteristics are impacted by the conjugation process, and how they influence your selection and development process

For biologics researchers working on:

  • Drug discovery, candidate selection, and formulation screening
  • Developability assessment of ADCs
  • Scale-up and manufacturing of protein-based therapeutics such as ADCs
access the Webinar!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.

Subscribe to Bioprocess Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Bioprocess Online

NanoTemper Technologies, Inc.